comparemela.com
Home
Live Updates
New data from the phase II CITYSCAPE trial show encouraging
New data from the phase II CITYSCAPE trial show encouraging
New data from the phase II CITYSCAPE trial show encouraging results with Roche's novel anti-TIGIT tiragolumab plus Tecentriq
After 2.5 years median follow-up, pre-planned exploratory analyses in the PD-L1-high population show clinically meaningful results, with overall survival not yet reached and continued progression-free... | December 10, 2021
Related Keywords
,
Roche Holding Ag Stock Exchange ,
News ,
Information ,
Press Release ,
After ,
Tears ,
Comedian ,
Exploratory ,
Analyses ,
N ,
The ,
Population ,
Show ,
Linically ,
Meaningful ,
Ith ,
Verall ,
Survival ,
Lot ,
Pet ,
Eached ,
End ,
Ontinued Rog Ch0012032048 ,